An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Dyslipidemia

Treatments: Drug: niacin (+) laropiprant; Drug: Comparator: placebo (unspecified)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00111891

MK0524A-032

2005_032

0524-032

Details and patient eligibility

About

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Full description

The duration of treatment is 7 days.

Enrollment: 575 patients

Sex: All

Ages: 25 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and females (ages 25-75)

Exclusion criteria

• A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind